BioPharma Systems — Operating Income (Loss)
Becton, Dickinson and Company BioPharma Systems — Operating Income (Loss) increased by 141.9% to $225.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 41.3%, from $383.00M to $225.00M. Over 4 years (FY 2021 to FY 2026), BioPharma Systems — Operating Income (Loss) shows a downward trend with a -18.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved profitability and operational performance of the segment.
Detailed definition
This metric represents the total operating profit or loss generated by the BioPharma Systems segment after accounting fo...
Peer comparison
Standard operating income metric used to compare the profitability of business segments across the industry.
bdx_segment_biopharma_systems_operating_income_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $492.00M | $83.00M | $692.00M | $564.00M | $537.00M | $489.00M | $585.00M | $628.00M | $549.00M | $349.00M | $439.00M | $734.00M | $602.00M | $622.00M | $453.00M | $141.00M | $383.00M | $224.00M | $882.00M | $861.00M | $552.00M | $140.00M | $93.00M | $225.00M |
| QoQ Change | — | -83.1% | +733.7% | -18.5% | -4.8% | -8.9% | +19.6% | +7.4% | -12.6% | -36.4% | +25.8% | +67.2% | -18.0% | +3.3% | -27.2% | -68.9% | +171.6% | -41.5% | +293.8% | -2.4% | -35.9% | -74.6% | -33.6% | +141.9% |
| YoY Change | — | — | — | — | +9.1% | +489.2% | -15.5% | +11.3% | +2.2% | -28.6% | -25.0% | +16.9% | +9.7% | +78.2% | +3.2% | -67.9% | -47.8% | -69.5% | +46.5% | +38.4% | +21.9% | -69.1% | -75.7% | -41.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — operating income (loss)?
- Becton, Dickinson and Company (BDX) reported biopharma systems — operating income (loss) of $225.00M in Q1 2026.
- How has Becton, Dickinson and Company's biopharma systems — operating income (loss) changed year-over-year?
- Becton, Dickinson and Company's biopharma systems — operating income (loss) decreased by 41.3% year-over-year, from $383.00M to $225.00M.
- What is the long-term trend for Becton, Dickinson and Company's biopharma systems — operating income (loss)?
- Over 4 years (2021 to 2026), Becton, Dickinson and Company's biopharma systems — operating income (loss) has grown at a -18.1% compound annual growth rate (CAGR), from $2.25B to $1.01B.
- What does biopharma systems — operating income (loss) mean?
- The total operating profit or loss for the BioPharma Systems segment.